Clinical Trial Update: Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial comparing subcutaneous versus intravenous administration of bortezomib in multiple myeloma patients in China across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Velcade (bortezomib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Multiple Myeloma Proved by Laboratory Tests | Phase 1, Phase 2 | Status: UNKNOWN